See every side of every news story

Published 20 days ago • loading... • Updated 20 days ago

Open Letter from Dean Maglaris, CEO of Cytogel Pharma

Summary by kalkinemedia.com

Cytogel is inspired by broader progress & committed to innovating in the field of pain management, striving to meet the evolving needs of patients globally. DARIEN, CT, UNITED STATES, February 3, 2025 /EINPresswire.com/ -- I am pleased to share that the FDA has just approved Journavx, a new pain medication for the treatment of moderate to severe acute pain, developed by Vertex Pharmaceuticals. This approval marks a significant milestone in pain …

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

1 Articles

All

Left

Center

Right

kalkinemedia.com

Open Letter from Dean Maglaris, CEO of Cytogel Pharma

Cytogel is inspired by broader progress & committed to innovating in the field of pain management, striving to meet the evolving needs of patients globally. DARIEN, CT, UNITED STATES, February 3, 2025 /EINPresswire.com/ -- I am pleased to share that the FDA has just approved Journavx, a new pain medication for the treatment of moderate to severe acute pain, developed by Vertex Pharmaceuticals. This approval marks a significant milestone in pain …

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated20 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

kalkinemedia.com broke the news in 20 days ago on Monday, February 3, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics